One Health Research Group, Universidad de Las Américas, Quito, Ecuador.
Navarrabiomed, Hospital Universitario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
JAMA Netw Open. 2024 Jul 1;7(7):e2421976. doi: 10.1001/jamanetworkopen.2024.21976.
No prior systematic review and meta-analysis has specifically verified the association of Mediterranean diet (MedDiet)-based interventions with biomarkers of cardiometabolic health in children and adolescents.
To review and analyze the randomized clinical trials (RCTs) that assessed the effects of MedDiet-based interventions on biomarkers of cardiometabolic health among children and adolescents.
Four electronic databases were searched (PubMed, Cochrane Library, Web of Science, and Scopus) from database inception to April 25, 2024.
Only RCTs investigating the effect of interventions promoting the MedDiet on cardiometabolic biomarkers (ie, systolic blood pressure [SBP], diastolic blood pressure [DBP], triglycerides [TGs], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], glucose, insulin, and homeostatic model assessment for insulin resistance [HOMA-IR]) among children and adolescents (aged ≤18 years) were included.
A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Data were extracted from the studies by 2 independent reviewers. Results across studies were summarized using random-effects meta-analysis.
The effect size of each trial was computed by unstandardized mean differences (MDs) of changes in biomarker levels (ie, SBP, DBP, TGs, TC, HDL-C, LDL-C, glucose, insulin, HOMA-IR) between the intervention and the control groups. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations approach.
Nine RCTs were included (mean study duration, 17 weeks; range, 8-40 weeks). These studies involved 577 participants (mean age, 11 years [range, 3-18 years]; 344 girls [59.6%]). Compared with the control group, the MedDiet-based interventions showed a significant association with reductions in SBP (mean difference, -4.75 mm Hg; 95% CI, -8.97 to -0.52 mm Hg), TGs (mean difference, -16.42 mg/dL; 95% CI, -27.57 to -5.27 mg/dL), TC (mean difference, -9.06 mg/dL; 95% CI, -15.65 to -2.48 mg/dL), and LDL-C (mean difference, -10.48 mg/dL; 95% CI, -17.77 to -3.19 mg/dL) and increases in HDL-C (mean difference, 2.24 mg/dL; 95% CI, 0.34-4.14 mg/dL). No significant associations were observed with the other biomarkers studied (ie, DBP, glucose, insulin, and HOMA-IR).
These findings suggest that MedDiet-based interventions may be useful tools to optimize cardiometabolic health among children and adolescents.
重要性:以前没有系统的综述和荟萃分析专门验证基于地中海饮食(MedDiet)的干预措施与儿童和青少年心血管代谢健康的生物标志物之间的关联。
目的:综述和分析评估基于 MedDiet 的干预措施对儿童和青少年心血管代谢健康生物标志物影响的随机临床试验(RCT)。
数据来源:从数据库成立到 2024 年 4 月 25 日,在四个电子数据库(PubMed、Cochrane 图书馆、Web of Science 和 Scopus)中进行了搜索。
研究选择:仅纳入了研究促进地中海饮食对心血管代谢生物标志物(即收缩压[SBP]、舒张压[DBP]、甘油三酯[TGs]、总胆固醇[TC]、高密度脂蛋白胆固醇[HDL-C]、低密度脂蛋白胆固醇[LDL-C]、葡萄糖、胰岛素和胰岛素抵抗稳态模型评估[HOMA-IR])影响的 RCT,这些研究的干预对象为儿童和青少年(≤18 岁)。
数据提取和综合:根据系统评价和荟萃分析的首选报告项目进行了系统评价和荟萃分析。研究结果由两名独立的评审员从研究中提取。使用随机效应荟萃分析总结了各研究的结果。
主要结果和测量:通过干预组和对照组之间生物标志物水平(即 SBP、DBP、TGs、TC、HDL-C、LDL-C、葡萄糖、胰岛素、HOMA-IR)变化的未标准化平均差异(MDs)计算每个试验的效应量。使用推荐评估、制定和评估方法评估证据质量。
结果:纳入了 9 项 RCT(平均研究持续时间为 17 周;范围为 8-40 周)。这些研究共涉及 577 名参与者(平均年龄 11 岁[范围 3-18 岁];344 名女孩[59.6%])。与对照组相比,基于 MedDiet 的干预措施与 SBP(平均差异,-4.75mmHg;95%置信区间,-8.97 至 -0.52mmHg)、TGs(平均差异,-16.42mg/dL;95%置信区间,-27.57 至 -5.27mg/dL)、TC(平均差异,-9.06mg/dL;95%置信区间,-15.65 至 -2.48mg/dL)和 LDL-C(平均差异,-10.48mg/dL;95%置信区间,-17.77 至 -3.19mg/dL)的降低以及 HDL-C(平均差异,2.24mg/dL;95%置信区间,0.34-4.14mg/dL)的增加显著相关。对于其他研究的生物标志物(即 DBP、葡萄糖、胰岛素和 HOMA-IR),没有观察到显著的相关性。
结论和相关性:这些发现表明,基于 MedDiet 的干预措施可能是优化儿童和青少年心血管代谢健康的有用工具。